Skip to main content
Article thumbnail
Location of Repository

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives

By Taiji Tsukamoto and Hiroshi Kitamura

Abstract

Intravesical instillation of bacillus Calmette Guérin (BCG) for the treatment of urothelial carcinoma (UC) of the bladder is based on the BCG-induced immune response, which eradicates and prevents bladder cancer. The results of recent studies have suggested that not only major histocompatibility complex (MHC)-nonrestricted immune cells such as natural killer cells, macrophages, neutrophils, etc., but also MHC-restricted CD8+ T cells play an important role and are one of the main effectors in this therapy. Better understanding of the mechanism of BCG immunotherapy supports the idea that active immunotherapy through its augmented T cell response can have great potential for the treatment of advanced UC. In this review, progress in immunotherapy for UC is discussed based on data from basic, translational and clinical studies. We also review the escape mechanism of cancer cells from the immune system, and down-regulation of MHC class I molecules

Topics: immunotherapy, urothelial cancer, cancer vaccine, LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, LCC:RC254-282, LCC:Internal medicine, LCC:RC31-1245, LCC:Medicine, LCC:R, DOAJ:Oncology, DOAJ:Medicine (General), DOAJ:Health Sciences
Publisher: Molecular Diversity Preservation International
Year: 2011
DOI identifier: 10.3390/cancers3033055
OAI identifier: oai:doaj.org/article:9680dd0d7991440faa27265f8014cbbc
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://doaj.org/search?source=... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.